Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.
Caveolin-1
Contralateral breast cancer
Genotype
Locoregional breast cancer recurrence
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
28
11
2022
accepted:
18
03
2023
medline:
15
5
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
Caveolin-1 (CAV1) has been implicated in breast cancer oncogenesis and metastasis and may be a potential prognosticator, especially for non-distant events. CAV1 functions as a master regulator of membrane transport and cell signaling. Several CAV1 SNPs have been linked to multiple cancers, but the prognostic impact of CAV1 SNPs in breast cancer remains unclear. Here, we investigated CAV1 polymorphisms in relation to clinical outcomes in breast cancer. A cohort of 1017 breast cancer patients (inclusion 2002-2012, Sweden) were genotyped using Oncoarray by Ilumina. Patients were followed for up to 15 years. Five out of six CAV1 SNPs (rs10256914, rs959173, rs3807989, rs3815412, and rs8713) passed quality control and were used for haplotype construction. CAV1 genotypes and haplotypes in relation to clinical outcomes were assessed with Cox regression and adjusted for potential confounders (age, tumor characteristics, and adjuvant treatments). Only one SNP was associated with lymph node status, no other SNPs or haplotypes were associated with tumor characteristics. The CAV1 rs3815412 CC genotype (5.8% of patients) was associated with increased risk of contralateral breast cancer, adjusted hazard ratio (HR CAV1 polymorphisms were associated with increased risk for locoregional recurrence and contralateral breast cancer. These findings may identify patients that could derive benefit from more tailored treatment to prevent non-distant events, if confirmed.
Identifiants
pubmed: 37017811
doi: 10.1007/s10549-023-06919-x
pii: 10.1007/s10549-023-06919-x
pmc: PMC10175335
doi:
Substances chimiques
Caveolin 1
0
CAV1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
335-347Subventions
Organisme : Cancerfonden
ID : CAN 20 0763
Organisme : Region Skåne
ID : ALF 40620
Organisme : Region Skåne
ID : ST-ALF
Organisme : Region Skåne
ID : Yngre ALF
Informations de copyright
© 2023. The Author(s).
Références
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Cancer Lett. 2012 Nov 28;324(2):142-51
pubmed: 22643115
Int J Cancer. 2018 Jan 15;142(2):347-356
pubmed: 28921573
Mol Cancer Res. 2020 Apr;18(4):644-656
pubmed: 31900313
Breast Cancer Res Treat. 2022 Jun;193(3):535-544
pubmed: 35426541
Virchows Arch. 2020 Aug;477(2):317-320
pubmed: 32080761
Pathol Res Pract. 2019 Jan;215(1):151-158
pubmed: 30463805
Br J Cancer. 2011 Nov 22;105(11):1676-83
pubmed: 22033271
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Trends Endocrinol Metab. 2011 Aug;22(8):318-24
pubmed: 21592817
Front Genet. 2020 Feb 28;11:157
pubmed: 32180801
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Breast Cancer Res Treat. 2012 Jan;131(1):1-15
pubmed: 21901387
Int J Mol Sci. 2022 Feb 24;23(5):
pubmed: 35269622
J Biol Chem. 2002 Mar 8;277(10):8635-47
pubmed: 11739396
Sci Rep. 2021 Jun 17;11(1):12781
pubmed: 34140615
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2
pubmed: 23535729
Breast. 2022 Aug;64:29-34
pubmed: 35468477
Breast Cancer Res. 2015 Aug 05;17:102
pubmed: 26242876
J Clin Invest. 2018 Apr 2;128(4):1538-1550
pubmed: 29528335
Transl Oncol. 2022 Aug;22:101464
pubmed: 35660849
Nat Rev Clin Oncol. 2017 Oct;14(10):595-610
pubmed: 28561071
Diabetes. 2011 Feb;60(2):448-53
pubmed: 21270257
Br J Cancer. 2016 Jul 26;115(3):382-90
pubmed: 27280635
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):380-394
pubmed: 29382703
Breast Cancer Res Treat. 2013 Aug;140(3):577-85
pubmed: 23912958
Cancer Cell Int. 2021 Jul 21;21(1):389
pubmed: 34289846
Int J Cancer. 2018 Nov 1;143(9):2092-2104
pubmed: 29524224
Breast Cancer Res Treat. 2009 Sep;117(2):401-8
pubmed: 19148746
Breast Cancer Res Treat. 2012 Jun;133(3):831-41
pubmed: 22147079
Genome Biol. 2004;5(3):214
pubmed: 15003112
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
Dtsch Arztebl Int. 2010 Jan;107(4):50-6
pubmed: 20165700
BMC Med Genomics. 2021 Nov 9;14(1):265
pubmed: 34753501
Breast. 2019 Apr;44:1-14
pubmed: 30580169
Cancer Metastasis Rev. 2020 Jun;39(2):435-453
pubmed: 32458269
Breast Cancer Res Treat. 2017 Oct;165(3):709-720
pubmed: 28677011
FEBS Lett. 1998 Jun 16;429(3):330-6
pubmed: 9662443
Medicine (Baltimore). 2021 Jun 18;100(24):e26186
pubmed: 34128850
Ann Oncol. 2014 Feb;25(2):339-45
pubmed: 24347518
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Front Oncol. 2021 Aug 13;11:705911
pubmed: 34485137
PLoS One. 2014 Mar 07;9(3):e90918
pubmed: 24608114
Pathol Res Pract. 2019 Sep;215(9):152518
pubmed: 31303379
Am J Physiol Cell Physiol. 2003 Jul;285(1):C222-35
pubmed: 12660144